Royaume-Uni - anglais - VMD (Veterinary Medicines Directorate)

chanelle pharmaceuticals manufacturing ltd - pentosan polysulphate sodium - solution for injection - anti inflammatory - dogs

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

headway investments pty ltd - pentosan polysulfate sodium - parenteral liquid/solution/suspension - pentosan polysulfate sodium mineral-sodium active 100.0 mg/ml - musculoskeletal system

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

chanelle pharmaceuticals manufacturing limited - pentosan polysulfate sodium - parenteral liquid/solution/suspension - pentosan polysulfate sodium mineral-sodium active 100.0 mg/ml - musculoskeletal system

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - gastroenterology & urology - the sentosa sq crc panel is a next generation sequencing-based in vitro diagnostic test that simultaneously detects hot spot mutations in 11 genes from formalin-fixed paraffin-embedded (ffpe) samples that have previously demonstrated clinical relevance in the management of patients with colorectal cancer (crc). this panel is intended to be used on the sentosa sx101 with the sentosa sx ffpe ii gdna kit in conjunction with the sentosa st401 and sentosa sq301 instruments. the sentosa sq crc panel is intended to be used as a test to aid the oncologist in clinical decision-making. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test or disease monitoring.

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - microbiology - the vela sentosa sq hcv genotyping assay is a next generation sequencing-based in vitro diagnostic test intended for viral genotyping in patients diagnosed with hepatitis c virus infection from human plasma or serum. this test is intended to be used on the sentosa sx101 with the sentosa sx virus total nucleic acid plus ii kit in conjunction with the sentosa st401 and sentosa sq301 instruments. the genotyping information from this test will help in the management of patients with hcv. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test. hs code: 38220090

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - immunology - the sentosa sq hiv genotyping assay is a next generation sequencing-based in vitro diagnostic test intended for detecting hiv genomic mutations in protease, reverse transcriptase and integrase regions from plasma in patients diagnosed with hiv infection. this test is intended to be used on the sentosa sx101 with the sentosa sx virus total nucleic acid plus ii kit in conjunction with the sentosa sq301 instruments. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test. the sentosa sq hiv genotyping assay is not indicated for use as a screening test for hiv or as a diagnostic test to confirm the presence of hiv infection.

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - immunology - the sentosa sq melanoma panel is a next generation sequencing-based in vitro diagnostic test that simultaneously detects hot spot mutations in 10 genes from formalin-fixed paraffin-embedded (ffpe) samples that have previously demonstrated clinical relevance in the management of patients with melanoma. this panel is intended to be used on the sentosa sx101 with the sentosa sx ffpe ii gdna kit in conjunction with the sentosa st401 and sentosa sq301 instruments. the sentosa sq melanoma panel is intended to be used as a test to aid the oncologist in clinical decision-making. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test or disease monitoring.

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - immunology - the sentosa sq nsclc panel is a next generation sequencing-based in vitro diagnostic test that simultaneously detects hot spot mutations in 11 genes from formalin-fixed paraffin-embedded (ffpe) samples that have previously demonstrated clinical relevance in the management of patients with non-small cell lung cancer. this panel is intended to be used on the sentosa sx101 with the sentosa sx ffpe ii gdna kit in conjunction with the sentosa st401 and sentosa sq301 instruments. the sentosa sq nsclc panel is intended to be used as a test to aid the oncologist in clinical decision-making. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test or disease monitoring. hs code: 38220090

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - immunology - the sentosa sq thyroid cancer panel is a next generation sequencing-based in vitro diagnostic test that simultaneously detects hot spot mutations in 10 genes from formalin-fixed paraffin-embedded (ffpe) samples that have previously demonstrated clinical relevance in the management of patients with thyroid caner. this panel is intended to be used on the sentosa sx101 with the sentosa sx ffpe ii gdna kit in conjunction with the sentosa st401 and sentosa sq301 instruments. the sentosa sq thyroid cancer panel is intended to be used as a test to aid the oncologist in clinical decision-making. results should be used in conjunction with other available laboratory and clinical information and are not intended for use as a stand-alone diagnostic test or disease monitoring. hs code: 38220090

Singapour - anglais - HSA (Health Sciences Authority)

vela operations singapore pte. ltd. - immunology - the sentosa® sq hiv-1 genotyping assay v2.0 (4x24) is a next generation sequencing (ngs) - based in vitro diagnostic test - intended for use in detecting hiv genomic mutations (in the protease, reverse transcriptase and integrase regions of the pol gene) that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring and treating hiv-1 infection. this test is used in adjunct to the therapeutic management of patients diagnosed with hiv-1 group m infection (including all subtypes and recombinant forms), and viral loads with at least 1,000 rna copies per ml in k2/k3 edta plasma specimens. the sentosa® sq hiv-1 genotyping assay v2.0 (4x24) is not indicated for use as a screening test for hiv or as a diagnostic test to confirm the presence of hiv infection.